PRospective Multiple Myeloma Impact Study (PROMMIS)



We are doing this study to learn if the MMprofiler test can help your doctor in making decisions about your treatment. The MMprofiler genomic test will look at a large number of normal genes. The test will predict risk of your multiple myeloma by assessing whether these genes are turned on or off in your cancer cells. The purpose of this research is to study whether this test can help your doctor to determine what treatment will be best for your multiple myeloma.

As part of your normal medical care, your doctors will take a bone marrow sample. A small piece of this bone marrow sample will be used for the MMprofiler test. 

If you agree to participate in this study no additional examinations, blood tests, or x-rays will be performed above and beyond your regular medical care.

Your doctor will be asked to complete a questionnaire about his/her treatment intention for you before he or she receives the MMprofiler result and after he or she receives the MMprofiler result.

The results of MMprofiler and the questionnaires will be stored in a database with additional medical information about you and your multiple myeloma. This includes, but is not limited to, your age, race/ethnicity, other diagnostic tests, your treatment and the response to your treatment.  No personal information will be stored in the database, but there will be a code that links your identity to your data. Data will be collected at five (5) different time points:

  • Before the doctor receives the MMprofiler results
  • After the doctor receives the MMprofiler results
  • One (1) year after the MMprofiler test was done
  • Three (3) years after the MMprofiler test was done
  • Five (5) years after the MMprofiler test was done

Taking part in this study may or may not make your health better. However, the knowledge gained from this research may benefit future patients with multiple myeloma.

SparkCures ID 920
Trial Phase Observational Trial
Enrollment 250 Patients
Trial Sponsors
  • SkylineDx
NCT Identifier


Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

  • Are at least 18 years.
  • Have potentially active and active multiple myeloma according to IMWG criteria.
  • Are a candidate for systemic treatment.
  • Additional inclusion/exclusion criteria may apply.

The following criteria is provided for health care professionals.

  • Patient is at least 18 years old
  • Patients with Multiple Myeloma according to IMWG criteria or patients highly suspected of having Multiple Myeloma
  • No more than 8 weeks of first line therapy for Multiple Myeloma

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

Not Currently Accepting Patients

The following is a listing of trial locations that are not currently open and accepting patients.

New Jersey
John Theurer Cancer Center<br />Hackensack Meridian Health
New York
Weill Cornell Medicine<br />
Weill Cornell Medicine

New York, NY

North Carolina
Levine Cancer Institute<br />Atrium Health
Washington, D.C.
Georgetown Lombardi Comprehensive Cancer Center<br />Georgetown University
Medical College of Wisconsin<br />Froedtert Hospital


There are no resources, links or videos to display for this clinical trial.

SparkCures Verified

SparkCures is working closely with SkylineDx to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors